EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience

Mattia D'Antiga, Nicolò Danesin, Giovanni Leone, Marco Carraro, Greta Scapinello, Andrea Serafin, Francesco Angotzi, Alessandro Cellini, Andrea Visentin, Livio Trentin, Francesco Piazza

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06770-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2026. Verfasst von Mattia D'Antiga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Medicine, University of Padua and Azienda Ospedale Università Padova, Padua, Italy. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Lymphoma, Follicular, Antineoplastic Combined Chemotherapy Protocols, Antigens, CD20. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL) in Western countries, with 65 beign the average age at diagnosis [1]. First-line treatment regimens combining Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) have shown favorable outcomes in pivotal trials [2-4]. Their efficacy and safety in patients aged 70 or older, who often receive reduced doses, remain unclear. This retrospective study evaluated the impact of reduced Bendamustine Delivered Dose Intensity [DDI, calculated as the total amount of Bendamustine (mg/m²) administered divided by the time taken to complete the regimen, with imputation for missed cycles] on outcomes and toxicities in FL patients (grade 1-3a) aged 70 or older treated with B-R or B-G between January 2014 and December 2023 at our center. Patients were categorized in reduced intensity (Low-DDI) and full intensity (High-DDI), based on the median DDI of the cohort. Efficacy was evaluated in the low DDI vs. high DDI setting, while toxicity outcomes were evaluated in the elderly (age ≥ 70 < 75 years) vs. very elderly (age ≥ 75yrs) population. Primary outcomes included progression-free survival (PFS) and overall survival (OS). Secondary outcomes included response rates, Progression of disease at 24 months (POD24) and toxicities. Among 139 FL patients, 39 met inclusion criteria (median follow-up: 73 months). Median OS was 31.5 vs. 65.0 months (p 0.238) and median PFS was 20.5 vs. 28.0 months (p = 0.081) for low- (n = 20) and high-DDI (n = 19), respectively. ORR was 78.9% vs. 100% (p = 0.105); CRR was 36.8% vs. 72.2% (p = 0.067). POD24 rates were similar (29.4% vs. 22.2%, p = 0.711). Patients were significantly older in the low-DDI group; other baseline features were comparable. Toxicity analysis showed no significant difference in grade ≥ 3 hematologic (p = 0.399) or non-hematologic (p = 0.920) events, or rate of hospitalization (p = 0.378) between elderly and very elderly. Secondary primary malignancies (SPM) occurred in 13 patients (34.2%), with no difference between groups. These findings support the feasibility of bendamustine dose reduction in elderly FL patients, showing no significant compromise in efficacy or increased toxicity. However, larger prospective studies are needed to confirm optimal dosing strategies in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bendamustine HydrochlorideLymphoma, FollicularAntineoplastic Combined Chemotherapy ProtocolsAntigens, CD20HumansFemaleAgedRetrospective StudiesMaleRituximabAged, 80 and overAntibodies, Monoclonal, HumanizedTertiary Care CentersTreatment OutcomeAcademic Medical Centers

Substanzen

Bendamustine HydrochlorideRituximabAntibodies, Monoclonal, HumanizedobinutuzumabAntigens, CD20

Autor:innen und Institutionen

  • Hematology Unit, Department of Medicine, University of Padua and Azienda Ospedale Università Padova, Padua, Italy.
  • Hematology Unit, Department of Medicine, University of Padua and Azienda Ospedale Università Padova, Padua, Italy. francesco.piazza@unipd.it.

Zitieren

APA

D'Antiga, M., Danesin, N., Leone, G., Carraro, M., Scapinello, G., Serafin, A., Angotzi, F., Cellini, A., Visentin, A., Trentin, L., & Piazza, F. (2026). Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience. Annals of Hematology. https://doi.org/10.1007/s00277-026-06770-2

Vancouver

D'Antiga M, Danesin N, Leone G, Carraro M, Scapinello G, Serafin A, et al. Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience. Annals of Hematology. 2026. doi:10.1007/s00277-026-06770-2

BibTeX
@article{DAntiga2026,
  author = {D'Antiga, Mattia and Danesin, Nicolò and Leone, Giovanni and Carraro, Marco and Scapinello, Greta and Serafin, Andrea and Angotzi, Francesco and Cellini, Alessandro and Visentin, Andrea and Trentin, Livio and Piazza, Francesco},
  title = {Balancing safety and efficacy of Bendamustine plus anti CD20 regimens in elderly patients (> 70 y) with follicular lymphoma: a tertiary academic center experience},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06770-2}
}
Kostenlos starten →